Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Base Ten (Basea) -- Ignore unavailable to you. Want to Upgrade?

To: Dharmak2 who wrote (48)	5/5/1998 3:19:00 PM
From: Dharmak2	Read Replies (2) \| Respond to of 152

Major news and buy recommendation today on Base 10. With the recent management changes and the exit from the defense business, this co. is poised to ride the coattails of the rapidly growing and immense pharmaceutical business. Using its expertise from the defense business for safety critical products. BASEA has become a leader and pioneer in Manufacturing Execution Systems (MES) for pharmaceutical industry and the medical device manufacturing industry...Principle product has evolved over the last couple of years from PHARMASYST, to PHARM2, to the latest BASE10 ME, which should be released within the next 4-6 weeks...The system assists pharmaceutical makers in controlling costs and meeting the Current Good Manufacturing Practices (cGMP) required by the FDA for the quality of pharmaceuticals and the integrity of data that support their safety and effectiveness. This system has many checks and balances and security measures needed in critical pharmaceutical manufacturing facilities and therfore can also be used for chemicals, food products. medical devices, cosmetics, beverages and consumer packaged goods... The software is very broad in scope, allowing drug cos. to comply with cGMP requirements governing inspection procedures. Controls, storage, handling,sampling, testing, and disposal for each pharmaceutical batch, along with associated recordkeeping requirements...also verifies equipment and makes sure employees are certified to perform daily activities...New CEO Thomas Gardner, tells MarketScope, he sees substantial growth opportunities for MES software due to increasing pressure for manufacturing productivity, somthing lacking in pharmaceutical industry relative to other industries, and the current FDA compliance policy, which could shut down a whole plant that does not have adequate processing controls...The software operates on a PC-based system in an open client/server environment and is designed as a standard application. Growth beginning in Q2 '98 with sequential quarterly revenue gains going out the next couple of years..losses should shrink throughout '98 with the co, turning profitable sometime in '99... With $13 million in cash, a new management team, and a very exciting opportunity to participate in the rapid growth for MES systems for the pharmaceutical industry, think BASEA has huge potential with very little risk./Mark Arbeter